Search

Displaying results 241 - 250 of 10000 in total
  1. Pathway

    Sphingolipid Signaling (Receptor)

    smpdb.ca/view/SMP0524344
    Signaling

    Through these receptor‑specific G protein couplings—spanning cAMP suppression, Ca²⁺ mobilization, PKC activation, Rho GTPase–driven cytoskeletal remodeling, and PI3K/Akt and MAPK pathways—S1P orchestrates

    Drugs: Nitric Oxide · Calcium · Magnesium cation
    Enzymes: Sphingosine 1-phosphate receptor 2, Sphingosine 1-phosphate receptor 4
  2. Drug

    TOL-101

    go.drugbank.com/drugs/DB16980
    Investigational

    Synonyms: Murine IgM monoclonal antibody specific for the human alpha, beta T cell receptor
  3. Drug

    Trastuzumab duocarmazine

    go.drugbank.com/drugs/DB16342
    Investigational

    Trastuzumab duocarmazine is under investigation in clinical trial NCT03262935 (SYD985 vs. Physician's Choice in Participants With Her2-positive Locally Advanced or Metastatic Breast Cancer).

    Synonyms: conjugated to the pro-drug seco-duocarmycinhydroxyb, Immunoglobulin g1-kappa, anti-(homo sapiens erbb2 (epidermal growth factor receptor 2, receptor tyrosineprotein kinase erbb-2, egfr2, her2, her-2, p185cerbb2, neu, cd340)), humanized monoclonal antibodyCategories: HER2 (Human Epidermal Growth Factor Receptor 2) inhibitors
  4. Drug

    EDI-200

    go.drugbank.com/drugs/DB18188
    Investigational

    EDI-200 is a fusion protein consisting of human immunoglobim G1 constant region Fc region fused to the human receptor binding domain of ectodysplasin-A1.

    Synonyms: HUMAN IMMUNOGLOBULIN G1 CONSTANT REGION - HUMAN ECTODYSPLASIN-A1 RECEPTOR-BINDING DOMAIN FUSION PROTEIN
  5. Drug

    PBCAR20A

    go.drugbank.com/drugs/DB17189
    Investigational

    Synonyms: Allogeneic gene edited CD20-directed CAR (Chimeric Antigen Receptor) T cells, Allogeneic anti-CD20 CAR T cells
  6. Drug

    Urea

    go.drugbank.com/drugs/DB03904
    ApprovedInvestigational

    A compound formed in the liver from ammonia produced by the deamination of amino acids. … It is the principal end product of protein catabolism and constitutes about one half of the total urinary solids.

    Mixtures: Ti-U-lac Lotion, Ti-U-lac HC LotionProducts: Uramaxin TS, RE Urea
  7. Drug

    Becotatug

    go.drugbank.com/drugs/DB19069
    Investigational

    JMT101 in Combination With Osimertinib, Versus Cisplatin-pemetrexed in Participants With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Characterized by Epithermal Growth Factor Receptor

    Synonyms: Jmt101 (fully human monoclonal igg1 antibody targeting epidermal growth factor receptor (egfr)), Immunoglobulin G1, anti-(human epidermal growth factor receptor) (human-Mus musculus monoclonal JMT101 γ1-chain), disulfide with human-Mus musculus monoclonal JMT101 κ-chain, dimer
  8. Drug

    Olinvacimab

    go.drugbank.com/drugs/DB16265
    Investigational

    Olinvacimab is under investigation in clinical trial NCT03033524 (Trial to Evaluate the Safety of Ttac-0001(tanibirumab) in Recurrent Glioblastoma).

    Synonyms: Fully human monoclonal antibody targets vascular endothelial growth factor receptor 2, Immunoglobulin g1, anti-(human vascular endothelial growth factor receptor 2) (human monoclonal ttac-0001 heavy chain), disulfide with human monoclonal ttac-0001 light chain, dimer
  9. Drug

    Diltiazem

    go.drugbank.com/drugs/DB00343
    ApprovedInvestigational

    specificity to target both the cardiac and vascular smooth muscle. … Approved in 1982 by the FDA, it is a member of the non-dihydropyridine calcium channel blockers drug class.

    Products: Diltiazem T, Diltiazem TZ
  10. Drug

    Olopatadine

    go.drugbank.com/drugs/DB00768
    Approved

    An ophthalmic solution of olopatadine was approved by the FDA and European Union for the treatment of seasonal and perennial allergic conjunctivitis in 1996 and 2002, respectively. … [L6790] Olopatadine works by blocking the effects of histamine, which is a primary inflammatory mediator that causes inflammatory and allergic reactions.

    Products: TQ OLOFTAL® 0.2% SOLUCION OFTALMICA